
    
      The objective of this study was to assess the single dose bioequivalence of Roxane's
      Ropinirole tablets,0.25 mg, to ReQuip Tablets, 0.25 mg (GlaxoSmithKline) under fed conditions
      using a single dose, randomized, 2-treatment, 2-period, 2-sequence cross-over design.
    
  